AUTL News and Press, Autolus Therapeutics plc From 03/15/24

2024-03-15 05:23:07 ET Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Conference Call March 14, 2024, 08:30 AM ET Company Participants Olivia Manser - Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Confere...

2024-03-14 07:02:41 ET More on Autolus Therapeutics BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapie...

AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...

Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million upfront, plus underwritten offering of ADSs for $350 million, for gross proceeds of $600 million received in February 2024 Submitted a Biologics License Application (BLA) for obeca...

2024-03-13 12:32:48 ET More on Autolus Therapeutics BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapie...

LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP inspection by the MHRA in February 2024, Autolus’ N...

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘ Dual T-cell constant β ...

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights ...

2024-02-22 19:04:44 ET Summary BioNTech and Autolus have announced a strategic alliance to advance their autologous CAR-T programs toward market authorization. BioNTech, known for its COVID-19 vaccine, is diverting its focus back to oncology and has a diverse, but immature pipelin...

2024-02-16 07:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...